A61K 51/109
Immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
Official title: {immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies}
A61K51/109 (Immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies) appears on 62 US grants and 86 published applications in this corpus.
Search patents in A61K- Granted patents
- 62
- Published applications
- 86
- Assignees
- 30
- Inventors
- 125
- Latest grant
- 12 Aug 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1990 | 1 | 0 |
| 1991 | 1 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 2 | 0 |
| 1996 | 0 | 0 |
| 1997 | 3 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 1 |
| 2003 | 0 | 1 |
| 2004 | 0 | 4 |
| 2005 | 0 | 2 |
| 2006 | 1 | 2 |
| 2007 | 1 | 1 |
| 2008 | 1 | 3 |
| 2009 | 4 | 9 |
| 2010 | 1 | 2 |
| 2011 | 2 | 5 |
| 2012 | 6 | 5 |
| 2013 | 10 | 7 |
| 2014 | 6 | 9 |
| 2015 | 6 | 5 |
| 2016 | 5 | 4 |
| 2017 | 1 | 3 |
| 2018 | 0 | 0 |
| 2019 | 0 | 0 |
| 2020 | 0 | 3 |
| 2021 | 1 | 3 |
| 2022 | 2 | 3 |
| 2023 | 2 | 4 |
| 2024 | 2 | 1 |
| 2025 | 3 | 3 |
| 2026 | 0 | 6 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Cysteine linked nanobody dimers12 Aug 2025US 12,384,835 B2Ablynx N. V.
- Modular self assembly disassembly (SADA) technologies1 Jul 2025US 12,343,401 B2Memorial Sloan Kettering Cancer Center
- C-terminal lysine conjugated immunoglobulins4 Feb 2025US 12,214,050 B2Eisai R&D Management Co., Ltd.
- Methods and compositions for targeting disease related cell surface receptors using radiolabeled and/or cytotoxin labelled antibodies26 Nov 2024US 12,151,004 B2University of Saskatchewan
- Bispecific antibodies specific for treating hematological malignancies30 Apr 2024US 11,970,542 B2Fred Hutchinson Cancer Center
- Bispecific antibody compounds18 Jun 2026US 2026/0166185 A1Y-Mabs Therapeutics, Inc.
- Multivalent immunoconjugates for targeted radioisotope therapy21 May 2026US 2026/0137822 A1Abdera Therapeutics Inc.
- Vhh antibodies and uses thereof30 Apr 2026US 2026/0116990 A1Key2Brain AB
- Kidney targeting antibodies26 Feb 2026US 2026/0055180 A1Abdera Therapeutics Inc.
- Peptide linkers for construction and reducing aggregation of fusion polypeptides comprising such29 Jan 2026US 2026/0027222 A1
Most cited
By later US patents
- Prostaglandin E2 dual variable domain immunoglobulins and uses thereof85US 8,822,645 B2AbbVie Inc. · 2014
- Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins80US 7,534,427 B2Immunomedics, Inc. · 2009
- Macrocyclic congugates and their use as diagnostic and therapeutic agents49US 5,435,990 AThe Dow Chemical Company · 1995
- Immunoreactive heterochain antibodies42US 4,978,745 ACentocor, Inc. · 1990
- Bispecific single chain Fv antibody molecules and methods of use thereof42US 7,332,585 B2Fox Chase Cancer Center · 2008